We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+4.02%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$14.7B
AUM Growth
-$14.5M
Cap. Flow
+$16.2M
Cap. Flow %
0.11%
Top 10 Hldgs %
85.95%
Holding
111
New
8
Increased
15
Reduced
6
Closed
2

Top Buys

Rank Stock Value
1
NVTA
Invitae Corporation
NVTA
+$115M
2
IGMS
IGM Biosciences
IGMS
+$63.5M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$47.4M
4
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$26.6M
5
URGN icon
UroGen Pharma
URGN
+$24.4M

Top Sells

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$132M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$113M
3
CPRX
Catalyst Pharmaceutical
CPRX
+$6.49M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$5.15M
5
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$4.91M

Sector Composition

Rank Sector Weight
1 Healthcare 93.54%
2 Financials 0.01%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASMB icon
51
Assembly Biosciences
ASMB
$499M
$7.9M 0.05%
66,937
– –
MRKR icon
52
Marker Therapeutics
MRKR
$18.7M
$7.67M 0.05%
150,000
– –
APLS
53
DELISTED
Apellis Pharmaceuticals
APLS
$7.56M 0.05%
313,725
– –
CPRX
54
DELISTED
Catalyst Pharmaceutical
CPRX
$7.13M 0.05%
1,341,902
-1,217,559
-48% -$6.49M
HOOK
55
DELISTED
HOOKIPA Pharma
HOOK
$6.7M 0.05%
89,286
– –
ACOR
56
DELISTED
Acorda Therapeutics
ACOR
$6.41M 0.04%
18,605
+1,845
+11% +$1M
DERM
57
DELISTED
Dermira, Inc.
DERM
$5.79M 0.04%
906,943
– –
XBIT icon
58
XBiotech
XBIT
$68.9M
$5.45M 0.04%
521,327
+140,885
+37% +$1.15M
ALBO
59
DELISTED
Albireo Pharma Inc
ALBO
$5M 0.03%
250,000
– –
ARAV
60
DELISTED
Aravive, Inc. Common Stock
ARAV
$4.98M 0.03%
664,088
+179,141
+37% +$1.12M
MIST icon
61
Milestone Pharmaceuticals
MIST
$128M
$4.97M 0.03%
266,667
– –
ORTX
62
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$4.82M 0.03%
40,570
– –
HALO icon
63
Halozyme
HALO
$9.88B
$4.65M 0.03%
299,969
– –
NXTC icon
64
NextCure
NXTC
$20.4M
$4.63M 0.03%
12,500
– –
IFRX icon
65
InflaRx
IFRX
$243M
$4.39M 0.03%
+1,778,415
New +$5.17M
ANAB icon
66
AnaptysBio
ANAB
$1.54B
$3.96M 0.03%
113,086
– –
ACHN
67
DELISTED
Achillion Pharmaceuticals
ACHN
$3.94M 0.03%
1,095,359
– –
LKFT
68
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.81B
$3.83M 0.03%
25,072
– –
BLUE
69
DELISTED
bluebird bio
BLUE
$3.67M 0.03%
3,088
– –
NGM
70
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$3.46M 0.02%
250,000
– –
MIRM icon
71
Mirum Pharmaceuticals
MIRM
$6.54B
$3.35M 0.02%
+333,333
New +$4.09M
XLRN
72
DELISTED
Acceleron Pharma
XLRN
$3.31M 0.02%
83,900
– –
VYNE icon
73
VYNE Therapeutics
VYNE
$3.14M 0.02%
194
– –
HARP
74
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$2.93M 0.02%
21,429
– –
VKTX icon
75
Viking Therapeutics
VKTX
$3.88B
$2.92M 0.02%
425,000
– –
1 2
3
4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q3 2019 Portfolio in Review

As of Q3 2019, Baker Bros. Advisors held 111 positions worth $14.7B, down 0.1% from $14.7B the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Baker Bros. Advisors's Q3 2019 filing shows 8 new, 15 increased, 6 reduced and 2 closed positions. Its largest new stake was IGM Biosciences: 3,144,000 shares worth $55.8M. The largest sale was Array Biopharma Inc, an estimated $132M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier, followed by Financials and Technology.

  • Baker Bros. Advisors's largest Q3 2019 buy was IGM Biosciences: 3,144,000 shares worth $55.8M.
  • Baker Bros. Advisors added most to Invitae Corporation in Q3 2019, an estimated $115M increase.
  • Baker Bros. Advisors's biggest Q3 2019 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $113M.
  • Baker Bros. Advisors fully exited Array Biopharma Inc in Q3 2019, selling an estimated $132M.
  • Baker Bros. Advisors's ten largest holdings make up 86% of its $14.7B portfolio in Q3 2019.
  • Baker Bros. Advisors opened 8 new positions and closed 2 in Q3 2019.
  • Baker Bros. Advisors's portfolio value fell 0.1% quarter-over-quarter to $14.7B.

Based on Baker Bros. Advisors's 13F filing for Q3 2019, filed 14 Nov 2019.